Health Sciences
"
"#
% "
$
ev
rR
ee
rP
Fo
!
%
% $
"
&&
$'
($ )
&
*
w
ie
ly
On
http://mc.manuscriptcentral.com/ac-phm-vcy
Page 1 of 27
Health Sciences
Symptom experiences and adherence to HAART
The influence of symptom experiences and attributions on adherence to Highly Active
Anti-Retroviral Therapy (HAART): a six month prospective, follow-up study.
Fo
iew
ev
rR
ee
rP
ly
On
http://mc.manuscriptcentral.com/ac-phm-vcy
1
Page 2 of 27
Health Sciences
Symptom experiences and adherence to HAART
The influence of symptom experiences and attributions on adherence to Highly Active
Anti-Retroviral Therapy (HAART): a six month prospective, follow-up study.
Abstract
Objective: To examine changes in individuals’ experiences of symptoms over the first six
months of taking HAART and to assess the impact of symptom experiences and attributions
on adherence to HAART.
Methods: A prospective study where consecutive HIV positive individuals initiating HAART
Fo
completed validated questionnaires assessing their experiences of symptoms, depression,
beliefs about HAART and adherence, before starting treatment and after one, three and six
rP
months of treatment.
Results: Rates of low (<95%) adherence to HAART increased over time (p<0.001). Overall,
ee
the number of HIV or HAART related symptoms reported did not change significantly over
follow-up. However, symptom experiences differed between those reporting high (≥95%)
rR
adherence and those reporting low adherence. Individuals reporting high adherence
experienced a decrease in symptoms they attributed to HIV (p<0.05), and a decrease in the
ev
symptoms they attributed to HAART side effects (p<0.05) over time.
This decrease in
symptoms over time was not seen among individuals reporting low adherence. A lack of
necessity for HAART (p<0.05).
iew
symptomatic improvement was associated with increasing doubts about the continued
Conclusions: The findings suggest that adherence to HAART is influenced by individuals’
On
experiences of both HIV and HAART related symptoms. Patients who experience persistent
symptoms while on HAART may begin to doubt their continued need for treatment and
respond by missing doses. These findings have implications for the development of evidence-
ly
based interventions to increase adherence.
Keywords: Adherence, HIV, HAART, symptoms, side-effects, treatment perceptions
WORD COUNT 2986
http://mc.manuscriptcentral.com/ac-phm-vcy
2
Page 3 of 27
Health Sciences
Symptom experiences and adherence to HAART
Introduction
Highly Active Anti-Retroviral Therapy (HAART) has greatly reduced morbidity and mortality
associated with HIV (Mocroft et al., 2003) however, low adherence seriously compromises the
efficacy of this treatment (Paterson et al., 2000; Wood et al., 2003). Maintaining high levels of
adherence over the long-term often proves difficult (Golin et al., 2002; Gross et al., 2001).
Identifying antecedents of nonadherence is crucial in order to develop effective strategies to
help people to achieve maximum benefit from HAART. While recent developments in the
Fo
formulation of antiretroviral medicines have addressed some of the practical barriers to
adherence, HAART continues to carry the risk of unpleasant or intolerable side effects. Even
rP
the most simple drug regimen may pose problems for adherence if it makes the individual feel
worse or does not improve symptoms.
ee
Symptoms are common among individuals receiving HAART (Bonfanti et al., 2000; Lucas et
rR
al., 1999) and have been associated with both non-adherence (Ammassari et al., 2001;
Chesney et al., 2000) and discontinuation of HAART (Mocroft et al., 2001; O’Brien et al.,
ev
2003). In order to develop appropriate interventions, several methodological issues need to
be addressed. Most studies to date have been cross-sectional and therefore unable to
iew
determine the direction of associations between symptoms and non-adherence. Little is
known about how symptoms change over time or what impact such changes have on
adherence. Most studies failed to distinguish between treatment side effects and disease
On
related symptoms. We need to understand the subjective distinction between symptoms of
disease and side effects of treatment in order to inform efforts to help individuals cope with
symptoms and improve the management of side effects. Studies have not adjusted for the
ly
possible influence of depression in their analyses, yet depression is common among people
with HIV (Ciesla & Roberts, 2001) and may impact on both symptom experiences (Watson &
Pennebaker, 1989) and adherence (Ammassari et al., 2004). Finally, the mechanisms by
which symptoms impact on adherence have not been adequately explored.
The Self-Regulatory Model (SRM) (Leventhal et al., 1987, 1992) proposes that illness related
behaviours are influenced by the way in which individuals interpret their symptom
http://mc.manuscriptcentral.com/ac-phm-vcy
3
Page 4 of 27
Health Sciences
Symptom experiences and adherence to HAART
experiences. Within this model, nonadherence is viewed as a ‘common sense’ response to a
lack of coherence between individuals’ beliefs about the illness, their experience of symptoms
and the doctors’ instructions. A qualitative study provided support for this model (Siegel et al.,
1999), with individuals reporting that they missed doses of their antiretroviral treatment in
order to avoid side-effects, and were prepared to accept the consequence of reduced clinical
benefit..
Fo
Horne (1997, 2003) proposed a method for operationalising the SRM to explain variations in
adherence to medication. He suggests that adherence is influenced by the way in which the
rP
individual judges their personal need for treatment relative to their concerns about potential
adverse effects. These judgements are influenced by the individual’s perception of their
ee
illness and their interpretation of symptom experiences. Previous research in a range of
conditions including HIV (Aikens et al., 2005; Brown et al., 2005, Horne & Weimnan, 2002;
rR
Horne et al., 2004, 2007; Llewellyn et al., 2003; Neame & Hammond, 2005) has provided
support for the necessity-concerns framework (NCF) in relation to adherence, however, no
HAART.
iew
ev
research has explored relationships between symptom experiences and beliefs about
The aims of this study were to 1. Explore individuals’ differential attributions of symptoms to
HIV or HAART 2. Explore changes in subjective experiences of HIV and HAART related
On
symptoms over time and 3. Examine associations between symptoms and beliefs about
HAART over time.
ly
Methods
Design
Patients attending an outpatient HIV clinic in Brighton, UK, completed validated
questionnaires assessing their adherence, experiences of symptoms and beliefs about
HAART before initiating treatment (0M) and after one (1M), three (3M) and six months (6M).
Data was collected between January 2000 and May 2004.
http://mc.manuscriptcentral.com/ac-phm-vcy
4
Page 5 of 27
Health Sciences
Symptom experiences and adherence to HAART
Participants
Patients were eligible for the study if they were not currently taking antiretroviral medication.
Participants were followed up over a year, and those who subsequently accepted a clinically
indicated offer of HAART formed the sample for this study. Exclusion criteria included having
insufficient understanding of English or being too ill to complete the study questionnaires.
Fo
Procedure
rP
Consecutive study-eligible individuals were referred by their HIV physician to a research
assistant. Standard procedures for consent were followed. Researchers attended weekly
ee
clinical meetings to identify participants who were eligible for a HAART recommendation on
the basis of contemporaneous guidelines (British HIV Association, 1997; 2001; 2003).
rR
Following a treatment recommendation, participants were given a questionnaire booklet to
complete along with a stamped addressed envelope. Medical files and pharmacy records
ev
were consulted to identify those who initiated HAART. These participants were sent follow-up
questionnaires one month (1M), three months (3M) and six months (6M) after initiating
iew
treatment. Telephone reminders were administered to optimise response rates.
On
Measures
Adherence
ly
Adherence to HAART was measured using the Medication Adherence Self Report Inventory
(MASRI) (Walsh, Mandalia & Gazard, 2002). Participants were asked to estimate on a visual
analogue scale of 0-100 the percentage of medication they had taken as prescribed over the
previous month. Participants who reported taking less than 95% of HAART medicines were
allocated to a ‘low adherence’ group, and those taking 95% or more of their medication as
prescribed allocated to a ‘high adherence’ group (Paterson et al., 2000).
Symptom experiences and attributions
http://mc.manuscriptcentral.com/ac-phm-vcy
5
Page 6 of 27
Health Sciences
Symptom experiences and adherence to HAART
Symptom experiences were assessed using the Identity subscale of the Illness Perceptions
Questionnaire (IPQ) (Moss-Morris et al., 2002; Weinman et al., 1996) comprising 11 ‘core’
symptoms common to a variety of illnesses and modified by the addition of 12 common
HIV/HAART related symptoms. There were two symptom scales, each comprising the same
23 symptoms. On one list, participants were asked to rate only those symptoms they believed
to result from HIV. On a second list participants were asked to rate only those symptoms they
associated with HAART. The scoring was conducted by first asking whether the person was
Fo
experiencing the symptom (yes/no) and second, by asking the participant to rate the severity
of each symptom they experienced on a scale of 1-5, where 1 = very mild, 2 = mild, 3 =
rP
moderate, 4 = severe, 5 = very severe. To ensure that only symptoms that were troublesome
to the individual were included, only scores rated 3-5 were used in the analyses, thereby
ee
excluding symptoms rated as ‘mild’ or ‘very mild’. Possible scores ranged from 0 to 23,
representing the number of symptoms the patient perceived to be moderate, severe or very
ev
Beliefs about HAART
rR
severe.
Beliefs about HAART were assessed using the Beliefs about Medicines Questionnaire-
iew
HAART specific version (BMQ-HAART) (Horne, Weinman & Hankins, 1999; Horne et al.,
2004; 2007). The BMQ-HAART comprises two scales: a HAART-necessity scale assessing
individuals’ perceptions of their personal need for HAART for controlling HIV and maintaining
On
health, and a HAART-concerns scale, assessing concerns about potential adverse effects of
HAART (e.g. worries about short and long-term side-effects and concerns about the
ly
disruptive effects of the HAART regimen on daily life). These were derived from studies of
patients’ perceptions of HAART (Cooper et al., 2002; Horne et al, 2004).
Participants were presented with a series of statements and asked to rate their level of
agreement with each item on a scale, where responses ranged from strongly agree (scored 5)
to strongly disagree (scored 1). Scores for individual items within each scale were summed..
http://mc.manuscriptcentral.com/ac-phm-vcy
6
Health Sciences
Page 7 of 27
Symptom experiences and adherence to HAART
A mean score was computed by dividing each total by the number of items, giving a range of
1 to 5 for both necessity and concerns scales.
Depression
The depression subscale of the Hospital Anxiety and Depression Scale (HADS) (Zigmond &
Snaith, 1983) was used to measure patients’ experience of depressive symptoms over the
previous month. Possible total scores range from 0-21, with higher scores indicating greater
Fo
depression.
rP
Clinical and demographic data
Clinical and demographic information, including age, sex, employment status, HIV acquisition
ee
risk, number of years since first HIV diagnosis, symptom classification (asymptomatic HIV,
symptomatic HIV or AIDS), whether the person had previously been prescribed antiretroviral
rR
treatment, CD4 count and viral load (log10), was extracted from participants’ medical files.
iew
ev
Statistical methods
Data were analysed using SPSS® 12.0 (SPSS Inc, Chicago, Ill). Clinical and demographic
characteristics were compared between those who completed the study and those with
missing data, using chi-square tests for categorical data and independent samples t-tests for
On
continuous variables. Clinical and demographic associations with adherence were also
examined in this way. NcNemar’s test was used to compare the number of patients reporting
low adherence at 1M and 6M. The frequency of individual symptoms was compared between
ly
high and low adherence groups using chi-square tests. Repeated measures ANCOVA was used
to assess changes in symptom experiences over time and the impact of these changes on
adherence at 6M, controlling for clinical variables that were associated with adherence in the
univariate analyses (prior antiretroviral use and time since HIV diagnosis), baseline depression
and adherence at 1M and 3M. Estimated marginal means (EMMs) were plotted. Associations
between changes in symptoms and medication beliefs were assessed using
http://mc.manuscriptcentral.com/ac-phm-vcy
Pearson’s
7
Page 8 of 27
Health Sciences
Symptom experiences and adherence to HAART
correlations and residualised change scores between baseline and six months measures (Cohen
& Cohen, 1983).
Results
Subjects
One hundred and twenty participants initiated HAART. Over the follow-up, 10 participants stopped
Fo
treatment, 2 died, 10 dropped out of the study and 18 missed one or more follow-up assessment
or returned questionnaires with missing data (Fig.1). Eighty participants (66.7%) provided the data
ee
rP
for this study.
Figure 1 about here
rR
Clinical and demographic characteristics of the sample are shown in Table 1.
ev
Table 1 about here
iew
Validity of adherence measure
Fifty-nine (96.7%) of those reporting high adherence at one month had an undetectable viral load
2
(<50 copies/ml) at six months compared to 16 (84.2%) of those reporting low adherence (χ =
On
3.87, p<0.05).
ly
Predictors of adherence
The number of participants reporting low adherence increased from 5 (6.3%) at 1M to 17
(21.3%) at 6M (McNemar’s test: p<0.001). Low adherence at 6M was associated with having
been diagnosed for a longer time (F (1,79) = 5.94, p<0.05) and having previously been
2
prescribed antiretroviral medication (χ =10.6, p<0.001).
Symptom attributions and impact on adherence
http://mc.manuscriptcentral.com/ac-phm-vcy
8
Page 9 of 27
Health Sciences
Symptom experiences and adherence to HAART
The twelve symptoms (rated moderate-severe) most commonly attributed to HIV and HAART
at 6M are shown in Figure 2. No individual symptoms were more frequently attributed to HIV
or HAART (McNemar’s test, all p>0.05).
Figure 2 about here
Symptoms attributed to HIV
Fo
At baseline, 66 (82.5%) participants reported ≥1 moderate-severe symptom they attributed to
HIV. The number of symptoms reported ranged from 0-21 (mean= 5.1, SD=4.5). At 6M, 42
rP
(58.8%) participants reported ≥1 moderate to severe symptom they attributed to HIV, the
number ranged from 0-17 (mean =3.0, SD=4.2).
ee
rR
Symptoms attributed to HAART side-effects
At 1M, 59 (73.8%) participants reported ≥1 moderate to severe symptom they attributed to
ev
HAART. The number of symptoms reported ranged from 0-17 (mean= 3.8, SD=4.3). At 6M,
47 (58.8%) of participants reported ≥1 moderate to severe symptom they attributed to
iew
HAART. The number of symptoms ranged from 0-17 (mean = 3.2, SD=4.4).
Table 2 about here
On
Relationships between symptom experiences and adherence
In cross-sectional analyses assessing the relationships between symptom experiences and
ly
adherence at six months, a greater number of symptoms associated with both HIV (t (78) =
2.249, p<0.05) and HAART (t (78) = 2.490, p<0.05) were associated with low adherence.
Individual HAART-related symptoms associated with low adherence were night-sweats
(p<0.01) and sexual problems (p<0.001). Individual HIV-related symptoms associated with
low adherence were: fatigue (p<0.01), sleep difficulties and altered sensation in hands or feet
(all p<0.05).
http://mc.manuscriptcentral.com/ac-phm-vcy
9
Page 10 of 27
Health Sciences
Symptom experiences and adherence to HAART
In repeated measures analysis, there was no significant main effect of time (F(1,66) =0.17,
p>0.1) or group (F(1,66) =0.11, p>0.1) on HIV-related symptoms. There was, a significant
group by time interaction (F(1,66) = 5.0, p<0.05). Figure 3 shows the main effects and
interaction (also reported in Table 2).
Figure 3 about here
Fo
There was no significant main effect of time (F(1,66)=0.03, p>0.1) or group (F(1,66)=1.07,
p>0.1) on HAART side-effects. There was a significant group by time interaction (F(1,66)=4.1,
rP
p<0.05). Figure 4 shows the main effects and interaction (also reported in Table 2).
ee
Associations between symptoms and beliefs about HAART
There was a significant inverse correlation between changes in symptom experiences and
rR
changes in necessity scores over time (HIV-symptoms r=-0.22, p<0.05; HAART symptoms r=0.22, p<0.05), consistent with an increase in symptoms being associated with a decrease in
ev
perceived necessity for HAART. Neither the change in HIV symptoms (r=0.09, p>0.1) nor
change in HAART symptoms (r=0.14, p>0.1) had a significant impact on individuals’ concerns
iew
about HAART.
ly
On
http://mc.manuscriptcentral.com/ac-phm-vcy
10
Page 11 of 27
Health Sciences
Symptom experiences and adherence to HAART
Discussion
Low adherence to HAART was associated with changes in individuals’ subjective experiences
of symptoms over time. People who experienced a lack of improvement in either the
symptoms they attributed to HIV or to HAART over the first six months of treatment were
more likely to report low adherence.
Fo
The results are consistent with previous findings linking symptoms to non-adherence to
HAART (Ammassari et al., 2001, Carrieri et al., 2001; Chesney et al., 2000; Duran et al.,
rP
2001; Gifford et al., 2000) and provide further insight into the nature of these relationships.
First, they show that the pattern of relationships between symptom experiences and
ee
adherence was similar with respect to both HIV and HAART related symptoms. This finding is
consistent with the SRM (Leventhal et al., 1982; 1987) suggesting that low adherence results
rR
from a lack of coherence between patients’ expectations of treatment and their experience of
symptoms. Second, the findings suggest a possible pathway through which symptom
ev
experiences may impact on adherence. In line with the model proposed by Horne (1997,
2003), they suggest that individuals who experience persistent symptoms after initiating
iew
HAART may begin to doubt their need for HAART and respond with low adherence. Third,
we showed that the results were unlikely to be an artefact due to depressed mood. Finally,
the fact that relationships between symptoms and adherence remained statistically significant
On
when earlier adherence was controlled for in the analysis is consistent with the experience of
persistent side-effects leading to non-adherence, rather than symptoms being the result of
earlier non-adherence.
ly
This study has several limitations. The sample consisted of predominately gay men. In order
to be representative of the wider HIV positive population in the UK, the study should be
replicated among other groups. Those who provided data were significantly older and more
likely to be antiretroviral naïve than the overall study sample. Since younger age (Carrieri et
al., 2001; Moatti et al., 2000) and having prior experience of antiretroviral treatment (Duran et
al., 2001; Mannheimer et al., 2002) have previously been associated with non-adherence, it is
http://mc.manuscriptcentral.com/ac-phm-vcy
11
Page 12 of 27
Health Sciences
Symptom experiences and adherence to HAART
likely that non-adherence was underestimated in this study. The symptom measure did not
encompass the wide spectrum of symptoms that may be experienced by people living with
HIV and those using HAART (e.g. CNS disturbance). It is therefore possible that some
participants could have been experiencing one or more severe symptom that was not covered
by the measure. Furthermore, we did not explore experiences of side effects that occur with
longer-term use of HAART, such as lipodystrophy. Depressed mood was measured only at
baseline. In order to fully control for the possible influence of depression on self-reported
Fo
symptoms and adherence, future studies should control for depression at every time-point.
The study relied heavily on self-report measures, including a self-report measure of
rP
adherence, which may be subject to a positive bias. Future studies, using objective measures
of adherence are required.
ee
The results of this study only represent two thirds of the participants originally recruited; those
rR
who remained in the study and on treatment for six months, and who provided complete data
at every follow-up. It is therefore likely that the sample was biased in terms of high adherence.
ev
Although our adherence categorisation was significantly related to viral suppression, with
iew
almost all (97%) of those in the high adherence group attaining a viral load <50 copies/ml at
the six month follow-up, 84% of those in the low adherence group also had an undetectable
viral load. In setting our cut-off point for high adherence we adopted the convention of 95%,
On
current at the time the study was conducted (Paterson et al., 2000). More recent studies
suggest that viral suppression may be achieved at lower rates of adherence to boosted
protease inhibitor (Gross et al., 2006) and NNRTI-based regimens (Bangsberg, 2006).
ly
Despite these limitations, our findings support the idea that non-adherence stems from
incongruence between individuals’ expectations and experiences of HAART and are
consistent with the theory that symptom experiences influence beliefs about treatment
(Horne, 1997, 2003). Specifically, they suggest that experiencing persistent symptoms
attributed to HIV or developing persistent symptoms related to HAART leads individuals to
doubt their continued need for HAART and this has been previously associated with non-
http://mc.manuscriptcentral.com/ac-phm-vcy
12
Page 13 of 27
Health Sciences
Symptom experiences and adherence to HAART
adherence (Horne et al., 2007). Further studies, with larger samples, are required in order to
fully test possible mediational relationships between symptoms, beliefs about HAART and
adherence.
Our findings are relevant to clinical practice and the design of interventions to promote
adherence to HAART. Intervening to alleviate symptoms may be an economical and clinically
Fo
relevant way to optimise adherence. Siegel et al. (1999) found that individuals tended to
resort to non-adherence before discussing symptoms with their clinicians. Clinicians should
rP
encourage patients to report any new symptoms so that the likely cause, duration and
possible treatment of each can be discussed. It should be noted that symptoms are subjective
ee
experiences, and those that are not considered to be clinically significant may be perceived
as severe by the patient. Indeed, previous studies found that low adherence was associated
rR
with patients’ perceptions of symptoms, but not by physician estimates of symptoms (Carrieri
et al., 2001; Duran et al., 2001) and that providers underestimated the presence and intensity
of symptoms (Justice et al., 1999). Furthermore, adherence may be increased by
ev
interventions which enhance individuals’ perceptions of their continued necessity for HAART
in the context of persistent HAART-side effects. Finally, the relationships identified in this
iew
study emphasise the need to continually develop new and better drugs which have fewer
side-effects and thereby result in better adherence.
On
References
ly
Aikens JE, Nease DE, Jr., Nau DP, Klinkman MS, Schwenk TL. (2005). Adherence to
maintenance-phase antidepressant medication as a function of patient beliefs about
medication. Annals of Family Medicine, 3, 23-30.
Ammassari A, Antinori A, Aloisi MS, Trotta MP, Murri R, Bartoli L, Monforte AD, Wu AW,
Starace F. (2004). Depressive symptoms, neurocognitive impairment, and adherence to
http://mc.manuscriptcentral.com/ac-phm-vcy
13
Page 14 of 27
Health Sciences
Symptom experiences and adherence to HAART
highly active antiretroviral therapy among HIV-infected persons. Psychosomatics, 45 (5),
394-402.
Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, Lo Caputo S, Narciso
P, Pauluzzi S, Carosi G, Nappa S, Piano P, Izzo CM, Lichtner M, Rezza G, Monforte A,
Ippolito G, d'Arminio Moroni M, Wu AW, Antinori A; AdICONA Study Group (2001). Selfreported symptoms and medication side effects influence adherence to highly active
Fo
antiretroviral therapy in persons with HIV infection. Journal of Acquired Immune Deficiency
Syndromes , 28 (5), 445-449.
rP
Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, Buono D,
ee
Eckholdt H, Howard A, Schoenbaum E. (2001). Antiretroviral therapy adherence and viral
suppression in HIV-infected drug users: comparison of self-report and electronic monitoring.
rR
Clinical Infectious Diseases, 33, 1417-1423.
ev
Bangsberg, DR. (2006). Less than 95% adherence to nonnucleoside reverse-transcriptase
inhibitor therapy can lead to viral suppression. Clinical Infectious Diseases, 43 (7), 939-41.
iew
Bonfanti P, Valsecchi L, Parazzini F, Carradori S, Pusterla L, Fortuna P, Timillero L, Alessi F,
Ghiselli G, Gabbuti A, Di Cintio E, Martinelli C, Faggion I, Landonio S, Quirino T. (2000).
On
Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study.
Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. Journal of Acquired
ly
Immune Deficiency Syndromes, 23 (3), 236-245.
BHIVA Guidelines Co-ordinating Committee. (1997). British HIV Association guidelines for
antiretroviral treatment of HIV seropositive individuals. Lancet, 349 (9058), 1086-92.
BHIVA Writing Committee; BHIVA Executive Committee.(2001).
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with
antiretroviral therapy. HIV Medicine, 2 (4), 276-313.
http://mc.manuscriptcentral.com/ac-phm-vcy
14
Page 15 of 27
Health Sciences
Symptom experiences and adherence to HAART
Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, Dunbar-Jacob J. (2005). Beliefs
about antidepressant medications in primary care patients: relationship to self-reported
adherence. Medical Care, 43, 1203-1207.
Butler JA, Peveler RC, Roderick P, Smith PWF, Horne R, Mason JC. (2004). Modifiable risk
Fo
factors for non-adherence to immunosuppressants in renal transplant recipients: A cross
sectional study. Nephrology Dialysis Transplantation, 19, 3144-3149.
rP
Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW. (2000).
ee
Self-reported adherence to antiretroviral medications among participants in HIV clinical trials:
the AACTG adherence instruments. Patient Care Committee & Adherence Working Group of
255-266.
ev
rR
the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care, 12(3),
Ciesla JA, Roberts JE. (2001). Meta-analysis of the relationship between HIV infection and
iew
risk for depressive disorders. American Journal of Psychiatry, 158 (5), 725-730.
Watson D, Pennebaker JW. (1989) Health complaints, stress, and distress: exploring the
central role of negative affectivity. Psychological Review, 96 (2), 234-254.
On
Cohen J, Cohen P. (1983). Applied multiple regression. Hillsdale, NJ: Erlbaum.
Carrieri P, Cailleton V, Le Moing V, Spire B, Dellamonica P, Bouvet E, Raffi F, Journot V,
ly
Moatti JP; APROCO study group (2001). The dynamic of adherence to HAART : results from
the French National APROCO cohort. Journal of Acquired Immune Deficiency Syndromes,
28(3),232-239.
Cooper V, Buick D, Horne R, Lambert N, Gellaitry G, Leake H, Fisher M. (2002). Perceptions
of HAART among gay men who have declined a treatment offer: preliminary results from an
interview-based study. AIDS Care14(3), 319-328.
http://mc.manuscriptcentral.com/ac-phm-vcy
15
Page 16 of 27
Health Sciences
Symptom experiences and adherence to HAART
Duran S, Spire B, Raffi F, Walter V, Bouhour D, Journot V, Cailleton V, Leport C, Moatti JP;
APROCO Cohort Study Group. (2001). Self-reported symptoms after initiation of a protease
inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trials,
;2(1), 38-45.
Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. (2000).
Fo
Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug
antiretroviral regimens. Journal of Acquired Immune Deficiency Syndromes,23 (5), 386-395.
rP
Golin C, Liu H, Hays RD, Miller LG, Beck CK, Ickovics J, Kaplan AH, Wenger N. A
ee
(2002).Prospective study of predictors of adherence to combination antiretroviral medication.
Journal of General Internal Medicine,17, 756-765.7.
rR
Gross R, Bilker WB, Friedman HM, Strom BL. (2001) Effect of adherence to newly initiated
ev
antiretroviral therapy on plasma viral load. AIDS,15, 2109-2117.
iew
Gross R, Yip B, Wood E, Bangsberg D, Montaner J, Hogg R. (2006). Boosted PI are more
th
forgiving of suboptimal adherence than non-boosted PI or NNRTI. 13
Conference on
Retroviruses and Opportunistic Infections Denver, Colorado, Feb 5-8,
On
Harrigan PR., Hogg RS., Dong WW., Yip B., Wynhoven B., Woodward J., Brumme CJ.,
ly
Brumme ZL., Mo T., Alexander CS., Montaner JS. (2005). Predictors of HIV drug resistance
mutations in a large antiretroviral-naïve cohort initiating triple antiretroviral therapy. Journal of
Infectious Diseases, 191 (3), 339-347.
Horne R. Representations of medication and treatment: Advances in theory and
measurement (1997).In Petrie KJ, Weinman JA. (Eds) Perceptions of Health and Illness
:Current Research and Applications (pp155-188)London: Harwood Academic Press.
http://mc.manuscriptcentral.com/ac-phm-vcy
16
Page 17 of 27
Health Sciences
Symptom experiences and adherence to HAART
Horne R. (2003). Treatment perceptions and self regulation. In Cameron LD, Leventhal H,
(Eds), The self-regulation of health and illness behaviour (pp138-153). London: Routledge.
Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J. (2004). Doubts about necessity
and concerns about adverse effects: Identifying the types of beliefs that are associated with
non-adherence to HAART. International Journal of STD and AIDS,15,38-44.
Fo
Horne R, Cooper V, Gellaitry G, Leake Date H, Fisher M. Patients' perceptions of HAART in
rP
relation to treatment uptake and adherence: The utility of the necessity-concerns framework.
Paper in Submission.
ee
rR
Horne R, Weinman J, Hankins M. (1999). The Beliefs about Medicines Questionnaire: The
development and evaluation of a new method for assessing the cognitive representation of
medication. Psychology and Health, 14, 1-24.
ev
iew
Horne R, Sumner S, Jubraj B, Weinman J, Frost S. (2001). Haemodialysis patients' beliefs
about treatment: Implications for adherence to medication and fluid-diet restrictions.
International Journal of Pharmacy Practice, 9,169-175.
On
Horne R, Weinman J. (2002). Self regulation and self management in asthma: Exploring the
role of illness perceptions and treatment beliefs in explaining non-adherence to preventer
ly
medication. Psychology and Health 17,17-32.
Justice AC, Rabeneck L, Hays RD, Wu AW, Bozzette SA. (1999). Sensitivity, specificity,
reliability, and clinical validity of provider-reported symptoms: a comparison with self-reported
symptoms. Outcomes Committee of the AIDS Clinical Trials Group. Journal of Acquired
Immune Deficiency Syndromes, 21(2),126-33.
http://mc.manuscriptcentral.com/ac-phm-vcy
17
Page 18 of 27
Health Sciences
Symptom experiences and adherence to HAART
Leventhal H, Cameron L. (1987). Behavioural theories and the problem of compliance.
Patient Education and Counselling, 10, 117-138.
Leventhal H, Diefenbach M, Leventhal EA. (1992). Illness cognition: using common sense to
understand treatment adherence and affect cognition interactions. Cognitive Therapy and
Research, 143-163.
Fo
Leventhal H, Nerenz DR, Sraus A. (1982). Self regulation and the mechanisms for symptom
appraisal. In Michanic D (Ed), Symptoms, illness behavior and help seeking (pp 55-86). New
rP
York: Watson Academic Publishers.
ee
Llewellyn C, Miners A, Lee C, Harrington C, Weinman J. (2003). The illness perceptions and
treatment beliefs of individuals with severe haemophilia and their role in adherence to home
rR
treatment. Health Psychology,18,185-200.
ev
Lucas GM, Chaisson RE, Moore RD. (1999). Highly active antiretroviral therapy in a large
urban clinic: risk factors for virologic failure and adverse drug reactions. Annals of Internal
iew
Medicine, 131(2), 81-87.
Mannheimer S, Friedland G, Matts J, Child C, Chesney M. (2002). The consistency of
On
adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency
virus-infected persons in clinical trials. Clinical Infectious Diseases, 34(8), 1115-1121.
ly
Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J. (2000). Adherence to
HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug
maintenance treatment. The Manif 2000 study group. AIDS,14(2),151-155.
Mocroft, A., Youle, M., Moore, A., Sabin, C., Madge, S., Lepri, A., Tyrer, M., Chaloner, C.,
Wilson, D., Loveday, C., Johnson, M., Phillips, A. (2001). Reasons for modification and
http://mc.manuscriptcentral.com/ac-phm-vcy
18
Health Sciences
Page 19 of 27
Symptom experiences and adherence to HAART
discontinuation of antiretrovirals: results from a single treatment centre. AIDS, 15 (2), 185194.
Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the
EuroSIDA study: an observational study. Lancet. 2003; 362:22–29.
Moss-Morris R, Weinman J, Petrie KJ, Horne R, Cameron L, Buick D. (2002). The revised
illness perception questionnaire (IPQ-R). Psychology and Health, 17(1), 1-16.
Fo
Neame R, Hammond A. (2005). Beliefs about medications: a questionnaire survey of people
with rheumatoid arthritis. Rheumatology, 44, 762-767.
rP
O’Brien, M.E., Clark, R.A., Besch, C., Myers, L., Kissinger, P. (2003) Patterns and correlates
ee
of discontinuation of the initial HAART regimen in an urban outpatient cohort. Journal of
Acquired Immune Deficiency Syndromes, 34 (4), 407-414.
rR
Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, Squier C, Wagener MM, Singh N.
ev
(2000). Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.
Annals of Internal Medicine, 133(1), 21-30.
iew
Pozniak A, Gazzard B, Anderson J, Babiker A, Churchill D, Collins S, Fisher M, Johnson M,
Khoo S, Leen C, Loveday C, Moyle G, Nelson M, Peter B, Phillips A, Pillay D, Wilkins E,
On
Williams I, Youle M; BHIVA Writing Committee BHIVA Executive Committee. (2003). British
HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral
ly
therapy. HIV Medicine, 1-41.
Siegel K, Schrimshaw EW, Dean L. (1999). Symptom interpretation: implications for delay in
HIV testing and care among HIV-infected late middle-aged and older adults. AIDS Care,11(5),
525-35.
http://mc.manuscriptcentral.com/ac-phm-vcy
19
Page 20 of 27
Health Sciences
Symptom experiences and adherence to HAART
Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP; APROCO cohort study group
(2002). Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients:
from a predictive to a dynamic approach. Social Science and Medicine, 54 (10), 1481-1496.
Walsh JC, Mandalia S, Gazzard BG.(2002). Responses to a 1 month self-report on
adherence to antiretroviral therapy are consistent with electronic data and virological
treatment outcome. AIDS, 16 (2), 269-77.
Fo
Weinman J, Petrie K, Moss-Morris R, Horne R. (1996). The Illness Perception Questionniare:
rP
A new method for assessing the cognitive representation of illness. Psychology and Health,
11, 431-445.
ee
Wood E., Hogg, RS., Yip B., Harrigan PR., O’Shaughnessy MV., Montaner JS. (2003). Effect
rR
of medication adherence on survival of HIV-infected adults who start highly active
antiretroviral therapy when CD4 count is 0.200-0.350 x 10 (9) cells/L. Annals of Internal
ev
Medicine 39 (10), 810-816.
Psychiatrica Scandanavica, 67(6),361-370.
iew
Zigmond AS, Snaith RP (1983). The Hospital Anxiety and Depression Scale. Acta
ly
On
http://mc.manuscriptcentral.com/ac-phm-vcy
20
Page 21 of 27
Health Sciences
Table 1: Sample demographics and clinical characteristics
Baseline clinical/demographic feature
Completed
Missing data
study n=80
n=40
P
Mean (SD)
40.0 (8.7)
34.0 (6.1)
<0.001
Transmission risk: gay man
n (%)
74 (92.5)
34 (85.0)
>0.1
White British
n (%)
70 (87.5)
27 (77.1)
>0.1
Years since HIV diagnosis
Mean (SD)
4.1 (4.2)
4.5 (5.0)
>0.1
Asymptomatic HIV
n (%)
25 (31.3)
12 (30.0)
>0.1
Symptomatic HIV
n (%)
36 (45.0)
15 (37.5)
>0.1
n (%)
19 (23.8)
13 (32.5)
>0.1
n (%)
22 (27.5)
22 (55.0)
<0.005
Mean (SD)
204 (131)
176 (124)
>0.1
Mean (SD)
5.3 (0.5)
5.3 (0.5)
>0.1
Fo
Age (years)
rP
AIDS
Prior experience of ART
Viral load (log10 copies/ml)
rR
ee
-3
CD4 count (mm /L)
Mean (SD)
5.1 (4.6)
5.6 (5.0)
>0.1
HAART-Necessity
Mean (SD)
4.0 (0.5)
3.6 (0.6)
<0.001
Mean (SD)
3.0 (0.6)
3.2 (0.6)
>0.05
Means (SD)
5.2 (4.3)
7.5 (4.7)
<0.01
HAART-Concerns
HADS-Depression
iew
ev
Moderate-severe symptoms (HIV)
ly
On
http://mc.manuscriptcentral.com/ac-phm-vcy
Health Sciences
Page 22 of 27
1
Table 2: Adjusted means for number of HIV and HAART symptoms reported
Moderate-severe HIV-related symptoms
Adherence
Follow-up
Mean
95% CI
High
baseline
5.1
4.0-6.2
High
1 month
4.3
3.0-5.6
High
3 months
2.7
1.8-3.7
High
6 months
2.4
1.4-3.4
Low
baseline
4.3
1.4-7.1
1 month
3.9
0.7-7.0
3 months
3.7
1.3-7.2
6 months
4.9
2.3-7.4
group
Low
rP
Low
Fo
Low
Moderate-severe HAART-related symptoms
Adherence
Mean
95% CI
1 month
3.8
2.9-4.8
High
3 months
2.5
1.5-3.4
High
6 months
2.6
1.6-3.6
Low
1 month
4.0
1.6-6.3
Low
3 months
3.8
1.5-6.1
Low
6 months
5.0
2.6-7.4
iew
ev
High
rR
ee
group
Follow-up
ly
On
1
The adjusted mean is the value of the group mean adjusted for prior treatment experience, time
since diagnosis, baseline depression and adherence at 1M and 3M.
http://mc.manuscriptcentral.com/ac-phm-vcy
Page 23 of 27
Health Sciences
Fig. 1: Study design and attrition
BASELINE Accept HAART n=120
Complete questionnaires: Symptoms checklists, HADS, BMQ-HAART
2 stopped treatment
1 died
6 dropped out
rP
Fo
1-MONTH FOLLOW-UP (n=111)
Symptoms checklist, BMQ-HAART, MASRI
3 stopped treatment
1 died
2 dropped out
rR
ee
3 MONTH FOLLOW_UP (n=105)
Symptoms checklist, BMQ-HAART, MASRI
5 stopped treatment
2 dropped out
ev
6 MONTH FOLLOW-UP (n=98)
Complete Symptoms checklist, BMQ-HAART
80 (66.7%) complete questionnaires at all time-points
w
ie
ly
On
http://mc.manuscriptcentral.com/ac-phm-vcy
Health Sciences
Page 24 of 27
Fig 2: Causal attribution of moderate-severe symptoms to HIV, HAART or both at six months.
Figure 1:Causal attribution of moderate-severe symptoms to HIV, HAART or both at six months.
fatigue (35%)
sleep difficulties (33%)
skin problems (30%)
sexual problems (30%)
diarrhoea (25%)
night sweats (24%)
Fo
loss of strength (21%)
altered sensation in hands/feet (21%)
upset stomach (21%)
rP
nausea (20%)
stiff joints (20%)
pain (19%)
10%
ee
0%
20%
30%
HIV only
40%
50%
HAART only
60%
70%
80%
90%
100%
Both HIV and HAART
Percentage for each causal attribution indicates reported cause for only those participants reporting the symptom.
Only the 12 most commonly reported symptoms are illustrated in this chart.
iew
ev
rR
ly
On
http://mc.manuscriptcentral.com/ac-phm-vcy
Page 25 of 27
Health Sciences
high adherence
low adherence
5.00
Fo
4.00
3.00
2.00
0M
rR
ee
rP
Estimated marginal means for moderate-severe
symptoms attributed to HIV
Fig 3: Adjusted means for number of HIV symptoms reported
1M
3M
6M
iew
ev
ly
On
http://mc.manuscriptcentral.com/ac-phm-vcy
Health Sciences
Page 26 of 27
5.00
high adherence
low adherence
4.50
4.00
Fo
3.50
3.00
2.50
2.00
1M
rR
ee
rP
Estimated marginal means for moderate-severe
symptoms attributed to HAART
Fig 4: Adjusted means for number of HAART symptoms reported
3M
6M
iew
ev
ly
On
http://mc.manuscriptcentral.com/ac-phm-vcy
Page 27 of 27
Health Sciences
Fo
iew
ev
rR
ee
rP
ly
On
http://mc.manuscriptcentral.com/ac-phm-vcy